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ABSTRACT
Skeletalchangesaccompanyingagingareassociatedwithbothincreasedriskoffracturesandimpairedfracturehealing,which,inturn,is
due to compromised bone regeneration potential. These changes are associated with increased serum levels of selected pro-
inflammatory cytokines, e.g., tumor necrosis factor a (TNF-a). We have used a unique model of bone regeneration to demonstrate
(1) that aged-related deficits in direct bone formation can be restored to young mice by treatment with TNF blockers and (2) that the
cyclin-dependent kinase inhibitor p21 is a candidate for mediation of the osteoinhibitory effects of TNF. It has been hypothesized
recently that TNF antagonists may represent novel anabolic agents, and we believe that the data presented here represent a successful
test of this hypothesis.  2010 American Society for Bone and Mineral Research.
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Introduction
T
he National Osteoporosis Foundation has estimated that
osteoporosis is a major public health threat for over 50% of
the population older than 50 years of age. Even patients in this
population who are taking potent pharmacologic substances
to lower their fracture risk remain at risk for fracture.
(1) In fact,
clinical and experimental evidence suggests that the entire aged
human population is at risk for impaired bone repair/regenera-
tion.
(1)
In humans, rats, and mice, fracture healing slows with
increasing age.
(2–4) Fractures of the femur heal more quickly
in younger than in older children, whereas mandibular fractures
heal faster in humans younger than than 18 years of age than in
those older than 18.
(3) Aging in adults is associated with greater
time to union for tibial and humeral fractures, as well as for
floating knee injuries.
(3) In adults older than 50 years of age,
increasing age correlates with reduction of the percent of unions
at 6 months after injury. A recent study of patients 35 to 92 years
of age demonstrated that short-term morbidity was common to
all fractures, with varying degrees of prolonged morbidity often
extending to at least a year postfracture.
(3) First fractures also
significantly increase the probability of subsequent fractures. It
also has been noted that age-related mortality/morbidity owing
to fractures is higher in males than in females.
(4)
Most fractures heal by a combination of endochondral and
direct (intramembranous, appositional) bone formation. In
fractures, direct bone formation results in the hard callus that
is responsible for the initial bridging and stabilization of the
fracture. In order to focus on direct bone formation in an aged
context, wehave developed a unique murine bone-regeneration
protocol that falls in the category of distraction osteogenesis
(DO). This model is a direct analogue of the clinical DO (limb-
lengthening)protocol.DOcanbeconsideredavariantoffracture
healing that significantly expands the volume of new bone
formed and challenges the proliferative capacity of the animal.
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114Direct bone formation in fracture and DO shares many common
features at the cellular and molecular levels.
(5) In fact, fatigue,
stress, and minimally displaced fractures all appear to heal by
direct bone formation.
(6,7) Taken together, the results of these
studies may explain the close correspondence between DO and
fracture healing demonstrated in models of chronic ethanol
exposure, lead exposure, diabetes, and aging.
(8–11) It also should
be noted that DO is used to treat delayed union, nonunion, and
infected fractures.
(12,13) Therefore, we postulate that deficits in
fracture healing involving direct bone formation in the clinic can
be modeled by DO in the laboratory.
Clinical experience with the DO technique has revealed an
age-related decrement in new bone density and in healing
index.
(14–16) These measures can be translated into an age-
related decrease in the rate of bone formation. In fact, in one
study, patient age was the most important factor in determining
new bone density.
(15) It has been demonstrated that the
histologic pattern of bone formation by DO in dogs, rabbits, rats,
and mice appears similar to that in humans.
(17,18) This suggests
that rodent models of DO will be useful as analogues to the
humanDOprocess andininvestigatingalterationsindirectbone
formation and repair during aging. In fact, recent work has
demonstrated age-related deficits in DO in both rat and mouse
models at 12 months of age or greater.
(8,19)
The DO process can be divided into two major phases. First is
the distraction phase, where the edges of a tibial fracture are
stretched apart, and where processes of direct bone formation
predominate in the slowly widening gap. This is followed by the
consolidation phase, beginning after the stretching stops, where
bone bridging (continuous osteoid/bone ‘‘bridge’’ from proximal
to distalcortices) and the osteoclast-mediated processes of bone
resorption and remodeling are initiated at each host bone
surfacetore-formthemedullarycanalandtoreplacewovenwith
lamellar bone. Actually, the presence of osteoclasts (TRAPþ
multinucleated cells) is first detected when the expanding DO
gap is almost bridged to begin re-formation of the medullary
canal.
IntheclinicalpopulationTNF,interleukin6(IL-6),andIL-1have
been consistently demonstrated to be increased in serum
in the aged population. Aging has been characterized as
‘‘inflamm-aging,’’ and a new discipline named osteoimmunology
has arisen in response to the high levels of these and other
cytokines in the aging population.
(20,21)
TNF is produced primarily as a product of the monocyte-
macrophage cell lineage and is responsible for proliferation,
inhibition, differentiation, and activation of a variety of cell
types.
(22) It also has been shown to be synthesized by bone
marrow stromal cells, T cells, and osteoblasts. TNF commonly
refers to two soluble proteins, TNF-a and TNF-b (lymphotoxin a),
which have a high degree of sequence homology and share
receptors. TNF-a exists in soluble and transmembrane forms
(tmTNF). TNF interacts with two receptors, TNF-R1 and -R2. Most
of TNF’s effects have been attributed to TNF-R1. Naturally
occurring TNF antagonists can be found in soluble forms, which
are derived from the extracellular domains of TNF-R1 (sTNFR1) or
-R2. These soluble receptors and/or commercially produced
antibodies to TNF also may bind to the tmTNF form, resulting in
what is termed reverse signaling (i.e., sTNFR1 binds tmTNF, which
initiates signal-transduction pathways). In this article, sTNFR1 will
refer specifically to two molecules of the extracellular domain of
the human TNF-R1 linked to a molecule of polyethylene glycol
(Pegsunercept),
(19)whereas sTNFR2will refertotwo moleculesof
the extracellular domain of the human TNF-R2 linked to the Fc
portion of human IgG1 (Etanercept/ Enbrel).
Previous studies have demonstrated the ability of TNF to
inhibit multiple osteoblast functions in vitro as well as fracture
repair in vivo.
(22–24) The signal-transduction pathways activated
by TNF binding to its receptors have been studied extensively in
several systems.
(25) In regard to TNF effects on osteoblastogen-
esis in vitro, recent work using fetal rat calvarial cells and a
murine calvarial osteoblastic cell line has demonstrated that TNF
(1) is a potent inhibitor of osteoblast differentiation from
precursor cells, (2) acts distal to insulin-like growth factor I (IGF-I)
and bone morphogenetic proteins (BMPs), (3) inhibits the
expression of RUNX2 and Osterix (osteoblast-associated tran-
scription factors) through MEK1 kinases, (4) suppresses vitamin
D–stimulated transcription owing to activation of transcription
factor NFkB, and (5) actions are mediated by TNFR1.
(26–28)
Though high levels of TNF are known to inhibit direct bone
formation in culture and in vivo, nevertheless, low doses can
enhance osteoblast proliferation in culture, and impaired bone
formation hasbeendemonstratedinTNFR1/R2double-knockout
mice.
(25,26) This suggests that a homeostatic level of TNF
signaling is required for optimal bone formation but that
unregulated or excessive expression results in pathology.
Further, in the paradigms named replicative, premature, and
cytokine-driven senescence, TNF signaling through TNFR1 has
been shown to induce p53, which, in turn, activates a cyclin-
dependent kinase inhibitor, i.e., p21 (Sdi1, WAF1, Cip1, Cdkn1a),
and a senescence marker in various cell types.
(22,31,32) Recently,
our colleagues have demonstrated that the effects of long-term
EtOH exposure on rat stromal osteoblasts in vitro include
inductionofp53,p21,andasenescentmarker.
(33)Thesefindings,
coupled with our published work demonstrating that chronic
ethanol exposure inhibits direct bone formation during distrac-
tion through the TNF signaling axis, suggested to us that
induction of p21 activity in aged mice undergoing DO may
provide one direct molecular and functional link between aging,
premature senescence, chronic ethanol exposure, and osteoin-
hibition. The availability of p21 knockout (KO) mice and the fact
that their skeletal development is normal presented the
opportunity for us to test for hypothetical p21 mediation of
TNF effects in the DO model (JAX on line, #003263).
In order to test the hypothesis that the elevated levels of TNF
associated with aged animals mediate the age-related inhibition
of direct bone formation characteristic of fracture repair and DO,
we have applied the DO bone-regeneration model to mice of
varying ages. Previous studies using this DO model have
demonstrated that aging is associated with elevated serum TNF
levels, inhibition of direct bone formation, and inhibition of
proliferation markers in osteoblast precursors.
(8,19) Further,
treatment of young mice with recombinant mouse tumor
necrosis factor (rmTNF) both inhibits bone formation and
decreases proliferation markers during DO.
(34,35) These results,
coupled with the crucial dependence of DO on sustained cellular
proliferation, suggest that aging in these models may be
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induciblegenesp53andp21.
(27,31)Theseresultsalsosuggestthat
directbone formation in the aged mouseDOmodel isanalogous
to the rat and human and therefore can be used to further study
the effects TNF signal modulation in aged mice.
Here we test the hypothesis that the elevated levels of TNF
associated with aged animals mediate the age-related inhibition
of bone formation demonstrated in fracture repair and DO. We
employed the mouse DO model to (1) test the effects of TNF
blockers on direct bone formation in aged animals and (2) test
for a potential role for p21 in the exogenous rmTNF-associated
osteoinhibition.
Materials and Methods
Animals
Virus-free adult male C57BL/6 mice were purchased from
Jackson Labs (Bar Harbor, ME). They were housed in individual
cages in temperature- (228C) and humidity-controlled (50%)
rooms having a 12 hours light per 12-hour dark cycle. All mice
were handled by animal care personnel for 5 to 7 days prior to
surgery. In all studies, the mice were assigned to respective
experimental groups with mean body weights equal to that of
the control group ( 4 g). All research protocols were approved
by the Institutional Animal Care and Use Committee (IACUC) of
the University of Arkansas for Medical Sciences.
Distraction protocol
Following acclimation and under Nembutal anesthesia, each
mouse underwent placement of an external fixator and
osteotomy to the left tibia.
(19,35,36) Four 27-gauge, 1.25-in
needles were manually drilled through the tibia (two proximally,
two distally). The titanium external fixator then was secured to
the pins. A small incision was made in the skin distal to the tibial
crest, and the soft tissue was carefully retracted to visualize the
bone.Asingleholewasmanuallydrilledthrough bothcorticesof
the mid-diaphysis, and surgical scissors were used to fracture the
cortex on either side of the hole. The fibula was fractured by
direct lateral pressure. The periosteum and dermal tissues were
closed with a single suture. Finally, buprenex (0.2 mg/kg) was
given by intramuscular injection after surgery for analgesia.
Distraction began 3 days after surgery (3-day latency) at a rate
of 0.075 mm b.i.d. (0.15 mm/day) and continued for 14 days.
After the distraction period, the mice were sacrificed, and the
distracted tibiae were harvested for radiographic and histologic
analyses. Trunk blood was collected for serum analyses.
Radiographic/histologic analyses
After 48 hours of fixation in 10% neutral buffered formalin, the
left tibiae were removed from the fixators for high-resolution
single-beam radiography and subsequent histologic processing.
For initial radiography, a Xerox Micro50 closed-system radio-
graphy unit (Xerox, Pasadena, CA, USA) was used at 40 kV (3 mA)
for 20 seconds using Kodak X-OMAT film. For quantification, the
radiographs were videorecorded under low-power (2  objec-
tive) microscopic magnification, and the area and density of
mineralized new bone in the distraction gaps were evaluated
by NIH Image Analysis 1.62 software/Image J software 1.30
(rsb.info.nih.gov/ij/). The measured distraction gap was outlined
from the outside corners of the two proximal and two distal
cortices, forming a quadrilateral region of interest. The
mineralized new bone area in the gap was determined by
outlining the regions with radiodensity equivalent to or greater
than the adjacent medullary bone. The percentage of new
mineralized bone area within the distraction gap (percent new
bone) was calculated by dividing mineralized bone area by total
gap area. Therefore, the percent new bone, as measured by the
radiograph analysis, is an estimate of new ‘‘mineralized’’ bone in
the entire gap.
(35,37)
After radiography, the distracted tibiae were decalcified in 5%
formic acid, dehydrated, and embedded in paraffin. Experience
in our laboratory has demonstrated that this achieves good
morphology in murine orthopedic tissues and does not appear
to significantly impair immunologic detection of many epi-
topes.
(38,39) Longitudinal sections 5 to 7 mm long were cut on a
microtome (Leitz 1512, Wetzlar, Germany) for hematoxylin and
eosin (H&E) staining. Sections were selected to represent a
central or near-central gap location. As detailed earlier, a
quadrilateral region of interest was outlined and recorded. Both
the proximal and distal endocortical (measured from the inside
corners of the cortices) and the intracortical (cortical wall
included) new bone matrices were outlined together from the
outside edges of the cortices, and the area was recorded as new
gap bone formation. The percentage of new gap bone area
within the DO gap (percent new bone) was calculated as earlier.
The percent new bone as measured by the histologic analysis is
an estimate of new gap bone formation, which would include
nonmineralized osteoid columns, embedded new sinusoids, and
maturing mineralized bone columns.
(35) We note that the
‘‘fibrousinterzone’’thatliesbetweentheproximalanddistalnew
bone formation fronts (i.e., the nonnew bone gap area) is
comprised of fibroblastic cells overlaying parallel collagen
bundles that are oriented along the distraction vector.
To be included in both radiographic and histologic analyses,
theDOsampleshadto(1)bewellaligned,(2)havenobrokenpin
sites, (3) have no bone chips within the DO gap and the animals
had to (4) have an intact ankle and (5) have had no significant
weight loss or health problems during the distraction period.
Experimental design
Study 1: To study the effects of a TNF antagonist on direct bone
formation, 24 (22-month-old) and 10 (3-month-old) male C57BL/
6 mice underwent the DO protocol. After the 3-day latency
period, the young and half the aged mice received a sub-
cutaneous injection of vehicle (phosphate-buffered saline, pH
7.4), whereas the remaining half of the aged mice received a
subcutaneous injection of sTNFR1 (8.0 mg/kg) every other day
for the 14-day distraction period. In a previous study, using the
same protocols, n¼14 (9-month-old) male C57BL/6 mice
received either vehicle or sTNFR1.
Study 2: A study comparing the effects of sTNFR1 and sTNFR2
(Etanercept/Enbrel) on direct bone formation in 21-month-old
mice was performed. Thirty male C57BL/6 mice underwent the
DO protocol and were divided into three equal groups: vehicle,
116 Journal of Bone and Mineral Research WAHL ET AL.sTNFR1-treated, and sTNFR2-treated. After the 3-day latency
period, the mice received subcutaneous injections of either
vehicle (PBS, pH 7.4), sTNFR1 (8.0 mg/kg), or sTNFR2 (8.0 mg/kg)
every other day for the 14-day distraction period.
Study 3: A study comparing the effects of rmTNF on 3-month-
old C57BL/6 versus p21 KO (JAX #003263) mice was performed.
Twenty-four male C57BL/6 and 24 male p21 KO mice underwent
the DO protocol. At the time of surgery, an Alzet pump (Model
1002) was inserted subcutaneously on the back of each mouse.
The mice in the control groups (n¼12 each) received vehicle
(PBS, pH 7.4) via Alzet, and those in the TNF groups (n¼12 each)
received 10 mg/kg per day of rmTNF via Alzet pump (R&D
Systems, Cat. No. 410-MT). Distraction began 3 days after surgery
and continued for 14 days.
Serum analyses
Serum samples were run using the Luminex xMAP technology in
the Pediatric Endocrinology Core Facility. The Lincoplex mouse
adipokine panels were used for TNF, IL-6, and insulin. Serum R&D
DuoSet ELISA kits were used for DKK-1 and IGF-BP-2, 3, and 6.
Serum R&D ELISA kits were used for human and mouse sTNFR1
and sTNFR2. Serum IGF levels were measured by IDS rat/mouse
ELISA kits. Serum mouse osteocalcin levels were measured by a
single-plex ELISA (Millipore).
In vitro analyses
Primary calvaria cells were isolated from new born mice (p21 KO
or wild type). Calvaria were dissected and subjected to four
sequential digestions in Earle’s MEM containing 200 U/mL
collagenase II at 378C. Cells in fractions 3 and 4 were collected
and combined. These calvarial cells were cultured at 3 to 5 10
5
cells per T-75 cm
2 flask in Earle’s MEM containing 10% FBS. After
6 days, cells were trypsinized and subcultured in a 6-well plate at
a density of 2 10
5 cells per well. Thefollowing day, the medium
was switched to serum-free medium containing 0.2% BSA for
16 hours. After the 16-hour serum starvation period, TNF-a
(25 ng/mL) or vehicle solution was added to the medium.
Twenty-four hours later, cells were lysed in RIPA buffer (50 mM
Tris-HCl, pH 7.5, 4.5 mM NaCl, 0.25% sodium deoxycholate, and
1% NP-40) containing protease inhibitors. Proteins then were
separated by 12% SDS-PAGE and electrotransferred to a PVDF
membrane. The membrane was probed with rabbit anti-p21
antibody (C-19, Santa Cruz Biotechnology, Inc., CA, USA). Blots
were developed using chemiluminescence according to the
manufacture’s instructions (Bio-Rad Immun Star Chemilumines-
cence Kit, Bio-Rad Laboratories, Hercules, CA, USA). Quantifica-
tion of blots was performed using a VersaDoc imaging system
(Bio-Rad Laboratories).
Statistical analyses
For statistical analysis, differences between group means were
determined by the Student’s t test or by one-way ANOVA. Also,
the Student-Newman-Keuls method was used for the pairwise
multiple comparisons, and the p values agreed with the ANOVA
values. All data are reported as mean standard error of the
mean (SEM). Differences were considered significant when
P<.05.
Results
Study 1: The effects of a TNF antagonist on direct bone
formation in 22-month-old male C57BL/6 mice compared
with 3-month-old mice
Radiographic analysis demonstrated a significant increase in the
mineralizedareaofdistractiongapsofsTNFR1-treatedagedmice
(55.2% 8.8%) and young mice (59.5% 10.9%) versus vehicle-
treated aged mice (27.4% 8.4%, P<.05). Histologic analysis
confirmed the dramatic increase in bone/osteoid formation
observed in the radiographs of the sTNFR1-treated aged mice
(76.1% 7.6%) versus the vehicle-treated aged controls
(31.2% 12.4%; P<.01). The vehicle-treated young mice
averaged 69.6% 4.4% (Fig. 1). In fact, 86% of the sTNFR1-
treated aged mice ‘‘bridged’’ (osteoid from proximal and distal
cortices from a continuous bridge across the gap) the gap during
distraction, whereas 45% of the young and none of the vehicle-
treated aged mice exhibited bridging. Serum samples were
taken to compare the hormonal milieu during DO. Serum
analyses confirmed high levels of sTNFR1 in treated mice only
(Table 1). Further comparisons between sera from young,
vehicle-treated aged, and sTNFR1-treated aged mice demon-
strated (1) increased serum levels of TNF and IL-6 in aged versus
youngmice,(2)unchangedlevelsofinsulin,IGF-I,IGF-BP-2and-3
[BP2,3], and (3) decreased levels of IGF-BP-6 [BP6] and DKK-1 in
both aged groups versus the young group (see Table 1). In
addition, serum osteocalcin levels were measured in all groups;
however, within the same experiment, only the aged controls
(47 2.1 ng/mL) were significantly (p<.001) different from the
aged þ sTNFR1-treated mice (69 1.0 ng/mL). In comparison
between groups, all the young mice had significantly higher
osteocalcin levels than the aged controls.
In addition, to test if sTNFR1 has ‘‘anabolic’’ effects
independent of age, we used n¼14 (9-month-old) middle-
aged male C57BL/6 mice who received either vehicle or sTNFR1
treatment in the same protocol. Radiographic analysis demon-
strated no significant differences in the mineralized area of
distraction gaps between the sTNFR1-treated and vehicle-
treated mice (vehicle: 68.3% 7.5%; treated: 73.3% 3.8%).
This finding suggests that the ‘‘anabolic’’ effects of TNF blockers
are age-related.
Study 2: The effects of sTNFR1 and sTNFR2
(Etanercept/Enbrel) on direct bone formation
in 21-month-old mice
Radiographic analysis demonstrated an increase in the miner-
alized DO gap area in the treated mice (sTNFR1: 46.5% 5.9%;
sTNFR2: 42.3%  7.6%) versus the aged vehicle controls
(26.4% 10.1%, P<.05). Histologic analysis also demonstrated
an increase in new bone/osteoid formation in the treated aged
mice (sTNFR1: 70.5% 4.9%; sTNFR2: 75.7% 6.3%) versus the
aged vehicle controls (45.8% 12.8%, P<.05) (Fig. 2). Serum
analyses confirmed the appropriate levels of sTNFR1 and sTNFR2
in treated mice only (Table 2).
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. Fig. 1. TNF blocker and aged bone repair. (A) Comparison of the
distracted tibial radiographs and the histograms demonstrated both
(1) an age-related difference in young versus old mice and (2) an
sTNFR1-associated increase in aged mice in percent mineralized area
and percent new bone/osteoid formation, respectively. Analysis of per-
cent mineralized area in radiographs demonstrated the following: Young
vehicle 59.5% 10.9% versus aged vehicle 27.4% 8.4%, P<.05, and
aged vehicle versus sTNFR1-treated aged 55.2% 8.8%, P<.05. Analysis
of percent new bone/osteoid formation in histologic sections confirmed
the radiographs and demonstrated an age-related decrease between
young vehicle (69.6% 4.4%) and aged vehicle (31.2% 12.4%, P<.01)
and an increase in the sTNFR1-treated aged mice (76.1% 7.6%, P<.01).
(B) Representative radiographs from young, aged, and aged sTNFR1-
treated mice. (C) Representative histograms from young, aged, and aged
sTNFR1-treated mice. The percent new bone/osteoid formation is shown
outlined by dashed lines.
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C57BL/6 versus p21 KO male mice
It has been demonstrated that (1) the DO process is highly
dependent on elevated and continuous levels of cell prolifera-
tion and (2) that TNF can inhibit DNA synthesis in several cell
types.
(29,38,40) Therefore, to begin to characterize the mechan-
isms underlying the TNF, and, by extension, the age-associated
inhibitionofdirectbonerepair,wetestedthehypothesisthatthe
induction by excess TNF of p21 (Cdkn1a), a known inhibitor of
cyclin-dependent kinases and therefore a putative inhibitor of
DNA synthesis, would result in delayed bone formation.
(41)
Radiographic analysis of the C57BL/6 mice demonstrated the
expected decrease in the mineralized DO gap area in the treated
mice (rmTNF: 41.3% 3.4%; vehicle: 60.1% 2.6%, P<.001).
However, the radiographs of the p21 KO mice demonstrated no
effects of the TNF treatment (rmTNF: 55.1% 7.4%; vehicle:
52.2% 6.1%, P¼.766). Further, histologic analyses corrobo-
rated both the expected decrease in the new bone/osteoid DO
gap area in the treated mice (rmTNF: 34.7% 4.3%; vehicle:
69.3% 2.6%, P<.001) and the resistance to the rmTNF
treatment in the p21 KO mice (rmTNF: 58.7% 6.3%; vehicle:
55.9% 6.4%, P¼.774) (Fig. 3). Serum samples verified that the
rmTNF-treated mice had elevated levels of both TNF and IL-6, a
known downstream target of TNF. TNF serum levels in rmTNF-
treated C57BL/6 mice were 32.8 1.1 pg/mL versus 5.4 0.5 pg/
mL (comparable with 3- to 9-month-old naive mice) in the
vehicle-treated mice. TNF serum levels in the rmTNF-treated p21
KO mice were 37.7 4.9 pg/mL versus 12.4 2.7 pg/mL in the
vehicle-treated mice. Similarly, IL-6 serum levels in the rmTNF-
treated C57BL/6 mice were 12.8 5.7 pg/mL versus 6.6 1.1 pg/
mL in the vehicle controls; whereas the IL-6 levels in the rmTNF-
treated p21 KO mice were 43.9 7.1 pg/mL versus 13.4 4.2 pg/
mL in the vehicle controls.
Based on the evidence that p21 KO mice were protected from
the osteoinhibitory effects of rmTNF, we investigated the effects
of short term in vitro administration of rmTNF on calvarial cell
cultures from p21 KO and control mice. rmTNF induced p21
protein levels (Fig. 4) significantly higher than vehicle-treated
wild-type calvarial cultures. As expected, p21 protein was not
detectable byour antibodyincalvariaisolated from p21KO mice,
validating the specificity of the antibody. In contrast to the
induction of p21 protein by rmTNF, no induction of p21 mRNA
was observed in rmTNF-treated cells (data not shown).
Discussion
TNF modulates bone formation in a dose-responsive manner;
since lack of TNF signaling can inhibit bone formation, low doses
can enhance osteoblast proliferation, and high doses can inhibit
boneformation invitroand invivo.
(29,30) TheinhibitionbyrmTNF
of endosteal new bone formation during DO in young mice
previously reported is of a similar magnitude as that caused by
chronic ethanol exposure and aging during DO in mice.
(19,35)
Therefore, these studies were conducted to test the hypothesis
that the age-related elevations of TNF may partially mediate the
deficits in bone formation/regeneration during DO previously
demonstrated in these pathologies.
Fig. 2. TNF blocker and aged bone repair. (A) Comparison of the dis-
tractedtibialradiographsandhistogramsdemonstrated bothansTNFR1-
and an sTNFR2-associated increase in aged mice in percent mineralized
area and percent new bone/osteoid formation, respectively. Analysis of
percent mineralized area in radiographs demonstrated the following:
Aged vehicle 26.4% 10.1% versus sTNFR1-treated aged 46.5% 5.9%
versus sTNFR2-treated aged mice 42.3%  7.6%, P<.05 for both treated
groups. Analysis of percent new bone/osteoid formation in histologic
sections confirmed the radiographs and demonstrated a TNF blocker–
associated increase over aged vehicle (45.8% 12.8%) versus sTNFR1-
treated (70.5% 4.9%, P¼.03) and sTNFR2-treated (75.7% 6.3%,
P¼.04). (B) Representative radiographs from aged, aged sTNFR1-treated,
andagedsTNFR2-treatedmice.(C)Representativehistogramsfromaged,
aged sTNFR1-treated, and aged sTNFR2-treated mice. The percent new
bone/osteoid formation is shown outlined by dashed lines.
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undergoing DO and treatment with TNF blockers Pegsunercept
[soluble human TNF receptor 1 derivative (sTNFR1)] or
Etanercept/Enbrel [soluble human TNF receptor 2 derivative
(sTNFR2)]. The results of these studies suggest that excess TNF
acts to inhibit new bone formation in this model system and that
both TNF blockers acted as potent ‘‘anabolic’’ agents that
reversed the aged osteoinhibitory repair phenotype. We
speculate that the TNF blockers are not true anabolic agents
but are relaxing the TNF-specific inhibitory signal-transduction
mechanismsthatblockexistingendogenousanabolicagents.An
example might be IGF-I because the serum levels actually were
higher in the aged mice than the young. This could be
interpreted as TNF-induced IGF-I resistance.
Several age-associated serum factors were measured. Given
age-associated induction of serum TNF levels, we expected
higher levels of DKK-1 in aged mice and lowered levels in TNF-
blocked mice.
(42) This was not the case; i.e., DKK-1 was lower in
aging mice and increased in aged mice treated with anti-TNF.
Several papers have demonstrated the negative effects of DKK-1
on bone in a variety of models.
(42,43) However, other papers
suggest that DKK-1 is necessary for bone formation.
(44,45) Finally,
perhaps more pertinent and in agreement with our findings, the
only other paper studying the effects of age on cellular DKK-1
levels have shown decreased DKK-1 levels with age.
(46) Based on
the evidence, we believe that age does decrease DKK-1 levels
and that the precise effects of DKK-1 on bone repair are complex
and require further study. As for the IGF-BP family, members
IGF-BP-1, -2, -3, -5, and -6 all have been hypothesized to be
associated with age-related changes in the skeleton.
(47–49) This
was the justification for including several BP members in the
serum analyses. No changes in IGF-BP-2 or -3 were noted, and
IGF-BP-6 was lower in aging and not reversed by TNF blockers.
The results do not support the preceding hypotheses, at least
with regard to direct bone formation in aged mice. As for the
serum osteocalcin levels, the only significant difference was
noted in the aged controls (lower) versus the sTNFR1-treated
Fig. 3. TNF and bone repair in p21 KO mice (data values not included,
justPvalues).(A)Comparisonofthedistractedtibialradiographs(percent
mineralized area) and the histograms (percent new bone/osteoid for-
mation) demonstrated an rmTNF-associated decrease in the wild type
(WT/C57BL/6) in both measures (P<.001) but not the p21 KO mice
(P¼.766 and P¼.774 respectively). (B) Representative radiographs from
young wild-type, young rmTNF-treated, p21 KO vehicle-treated, and
rmTNF-treated p21 KO mice. (C) Representative histograms from young
wild-type, young rmTNF-treated, p21 KO vehicle-treated, and rmTNF-
treated p21 KO mice. The percent new bone/osteoid formation is shown
outlined by dashed lines.
Table 2. Study 2: Serum Cytokine Analysis
msTNFR1 msTNFR2 hsTNFR1 hsTNFR2
AgedþVehicle 616.2 45.4 6091.5 518.2
1 3.0 1.4 31.9 19.8
AgedþsTNFR1 587.7 33.8 5177.7 576.2
2 4638.5 143.4
4 14.7 9.1
AgedþsTNFR2 606.5 53.9 7423.6 674.1
3 27.1 6.6 2945.1 201.6
5
YoungþVehicle 538.7 21.2 4008.7 119.6 ND ND
Values in pg/mL (m¼mouse); 1¼aged vs young, p¼.004; 2¼sTNFR1 vs sTNFR2, p¼.013; 3¼sTNFR2 vs young, p<.001; 4¼sTNFR1 vs aged or
sTNFR2, p<.001; 5¼sTNFR2 vs aged or sTNFR1, p<.001.
Fig. 4. In vitro effects of rmTNF on p21 protein levels by Western blot in
calvarial cultures from p21 KO and-wild type control (WT) mice.
Veh¼vehicle untreated.
120 Journal of Bone and Mineral Research WAHL ET AL.aged (higher). We speculate that modulation of TNF levels has
more of an effect in the aged mice than in their much younger
counterparts perhaps owing to increased sensitivity to excess
TNF in the aged. It may be important to note that these values
arenot markers ofhomeostatic responses to agingorexogenous
TNF; rather, they reflect serum changes while the animal
undergoes a significant repair/regeneration response.
We also provide evidence that TNF-induced p21 is a potential
candidate for mediation of the underlying osteoinhibitory
mechanisms. Evidence from the in vivo study demonstrates
that p21 KO mice are not deficient in direct bone formation
during DO and that they are significantly protected from the
osteoinhibitoryeffectsofrmTNF.Evidencefromtheinvitrostudy
demonstrates that rmTNF induces p21 protein in wild-type
calvarial cells but not in calvarial cells from p21 KO mice. These
results are consistent with the findings that TNF induces p21 in
many cell types and that p21 can inhibit proliferation in
osteoblasts.
(29,31,41) p21 was first described as a potent and
universal inhibitor of cyclin-dependent kinases and, as such, was
responsible for G1/S arrest after DNA damage and during
quiescence. Also, p21 has been associated recently with re-
plicative, premature, and cytokine-driven senescence.
(22,31–33)
Considering that (1) bone formation during DO depends on high
levels of sustained proliferation and (2)that proliferation markers
are significantly decreased in both age-related and exogenous
rmTNF-related inhibition of bone formation, one could hypothe-
size that p21 is acting solely to disrupt preosteoblast and
osteoblast proliferation. Consistent withthis hypothesis, TNF and
senescence induce cell arrest by p21 in mouse embryo
fibroblasts (MEFs), which can differentiate into osteoblasts and
could be considered very early osteoblast precursors.
(50–52)
Whether or not the DO gap contains the equivalent of MEFs
remains to be demonstrated; however, we have detected
markers of embryologic osteoblast precursors in the DO gap by
immunohistochemistry, i.e., runx 2 and twist 2/dermo 1
(unpublished observations).
(53) Further work will be needed to
test these hypotheses, especially because p21 also has been
shown to inhibit osteoblast differentiation, perhaps by interac-
tion with runx 2 and/or the WNT 4 promoter.
(41,54,55)
As with fracture healing, DO enhances demand for blood flow
but does so to a greater extent.
(14,56–59) Angiogenesis appears
crucial to both direct and endochondral bone formation.
(59) In
fact, it has been postulated that angiogenesis occurs before
osteogenesis in DO.
(59) This raises questions about the effects of
aging, TNF, and TNF antagonists on angiogenesis. We do
measure the percent new sinusoid area in the developing DO
gap, and we can identify endothelial cells by immunohisto-
chemistry. In our experience in young, old, and rmTNF-treated
mice after 14 days of distraction, direct bone formation is always
accompanied by and significantly positively correlated with
developing sinusoids. It has been demonstrated that chronic
ethanol exposure both induced TNF and inhibited proliferation
in endothelial cells.
(60) Also, in endothelial cells, TNF can activate
inflammatory responses and increase pathogenic angiogenesis
or can inhibit proliferation and increase apoptosis.
(61) Since TNF
can inhibit runx 2 activity in osteoblasts, it may be important to
note that runx 2 also can regulate endothelial cell prolifera-
tion.
(62) Therefore, the effects of age and/or TNF on the DO gap
are possibly the result of the combined effects on both
angiogenesis and osteogenesis.
Common clinical analogues of the experiments proposed here
are impaired fracture healing and healing after other orthopedic
procedures in aged patients.
(1–4) Blockage of cytokine-mediated
osteoinhibitory effects also could be clinically appropriate in
more orthopedic cases than just those with aging as a major risk
factor. For example, TNF has been proposed to mediate
orthopedic implant osteolysis.
(63) These results are also con-
sistentwithrecentstudiesthatdemonstrate(1)thatendogenous
TNF lowers maximum peak bone mass in mice and inhibits
osteoblastic Smad activation, (2) that blockade of TNF increased
a marker of bone formation in early postmenopausal women,
and (3) that elevated inflammatory markers, including TNF, are
prognostic for osteoporotic fractures.
(64–66) In fact, it has been
hypothesized thatTNFantagonistsmayrepresentnovelanabolic
agents, and we believe that the data presented here represent a
successful test of this hypothesis.
(64) Together these results
support future testing of pharmacologic interventions that
modulateTNFactivitiesforthepreventionofimpairedfractureor
orthopedic procedure healing in aged patients.
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